Sage Therapeutics is rated a Strong Buy due to ... mostly from lower R&D and general overhead. Still, we do not expect profitability in the near term. In our opinion, commercial traction from ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Among these, Sarepta Therapeutics crashed following a report ... Elevidys or lead to slow overall market adoption. Gilead Sciences, Inc.stock tumbled after the Wall Street Journal reported that ...

ProQR Therapeutics has turned to a new chief financial officer and fresh chief medical officer to support the next phase of growth for the RNA therapies developer. The Netherlands-based ...

7 analysts have shared their evaluations of Voyager Therapeutics (NASDAQ:VYGR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a ...

BOSTON--(BUSINESS WIRE)--RyCarma Therapeutics, Inc., a clinical-stage ... M.D., as its Chief Medical Officer (CMO). In this role, Dr. Tarka will lead the clinical development of surlorian (ARM210 ...

Most breakthroughs, from the basic science discoveries that reveal the ... through research and health care is also an investment in medical advancements and public health. But the uncertainty ...

The discovery of Mendeleev’s periodic table The first version of Mendeleev’s periodic table, published in 1869, was reportedly completed in just one day. Historians have pieced together what ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...